Beranda › Kanker Endometrium › Texas › San Antonio
Uji klinis Kanker Endometrium di San Antonio, TX
27 studi untuk Kanker Endometrium mencari peserta di lokasi sekitar San Antonio (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of PHST001 in Advanced Solid Tumors
Menerima pesertaFase 1
- START Center for Cancer Research - San Antonio, San Antonio
- University of Texas (UT) Health, San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Menerima pesertaFase 3
- Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Menerima pesertaFase 1/2
- START Center for Cancer Research, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
- The University of Texas Health Science Center at San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
- START - San Antonio, San Antonio
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Menerima pesertaFase 3
- USOR - TX Oncology - SA NE, San Antonio
- NEXT San Antonio, San Antonio
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Menerima pesertaFase 3
- Research Site, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Menerima pesertaFase 1
- NEXT San Antonio, San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Menerima pesertaFase 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Menerima pesertaFase 1
- Normunity Investigational Site, San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- START - San Antonio, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Texas Oncology - San Antonio, San Antonio
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Menerima pesertaFase 3
- Texas Oncology San Antonio Medical Center, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT San Antonio, San Antonio
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- START San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Menerima pesertaFase 1
- NEXT Oncology, San Antonio
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- START, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Menerima pesertaFase 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Menerima pesertaFase 2
- START San Antonio, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Menerima pesertaFase 1
- Dren Investigational Site, San Antonio
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Menerima pesertaFase 2/3
- Texas Oncology-San Antonio Medical Center, San Antonio
Uji klinis Kanker Endometrium di kota lain
- Houston, TX68 studi
- New York City, NY52 studi
- Boston, MA50 studi
- Arlington, VA39 studi
- Nashville, TN38 studi
- Los Angeles, CA34 studi
- St. Louis, MO29 studi
- Philadelphia, PA28 studi
- Columbus, OH25 studi
- Oklahoma City, OK25 studi
- Chicago, IL25 studi
- Queens, NY25 studi
Studi lain di San Antonio
- Kanker Paru Non-Sel Kecil59 studi
- Kanker Payudara47 studi
- Kanker Kolorektal46 studi
- Kanker Metastatik44 studi
- Kanker (semua jenis)41 studi
- Obesitas40 studi
- Diabetes Tipe 237 studi
- Kelebihan Berat Badan34 studi
- Kanker Ovarium31 studi
- Kanker Pankreas31 studi
- Kanker Prostat28 studi
- Kanker Paru26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.